Ernie Yulyaningsih serves as the Associate Director at Stealth NewCo, where she leverages her extensive background in neuroscience to drive innovative research initiatives in the neurodegeneration sector. With over 18 years of combined academic and industry experience, Ernie has honed her expertise in in vivo...
Ernie Yulyaningsih serves as the Associate Director at Stealth NewCo, where she leverages her extensive background in neuroscience to drive innovative research initiatives in the neurodegeneration sector. With over 18 years of combined academic and industry experience, Ernie has honed her expertise in in vivo and biomarker development, focusing on translating complex biological insights into clinically relevant applications. At Stealth NewCo, she plays a pivotal role in the design and execution of preclinical strategies for both small and large molecule programs, ensuring that the research aligns with the latest advancements in neurodegenerative disease understanding.
One of Ernie's key projects involves the identification and validation of clinically translatable biomarkers that can significantly enhance the drug development process. Her proficiency in brain histology and immunofluorescence techniques allows her to meticulously analyze neural tissue samples, providing critical insights into disease mechanisms. Additionally, her experience with advanced imaging techniques, such as Echo MRI, enables her to assess in vivo models with precision, thereby facilitating a comprehensive understanding of metabolic profiling in mouse models.
Ernie's leadership in colony management and her adeptness in grant writing further underscore her commitment to fostering a collaborative research environment. By integrating her skills in lineage tracing and hypothalamic explant culture, she not only contributes to the scientific community but also ensures that Stealth NewCo remains at the forefront of neurodegeneration research. Her dedication to customer service and stakeholder engagement enhances the translation of scientific discoveries into viable therapeutic options, ultimately aiming to improve patient outcomes in neurodegenerative diseases.
